Inclusion Criteria:  Male or Female that ages 18-85 year old; Having evidence of myocardial ischemia; Voluntarily participates in this study and signs the informed consent form (ICF); Sufficiently compliant with the study protocol and agreed to receive follow-up at 1 month ±7 days, 6 months ±14 days, 9 months ±30 days, 12 months ±30 days, and 24 months ±30 days, of which angiography was required at 9 months ±30 days; Angiography confirmed as de novo bifurcation lesion with side-branch stenosis (diameter) ≥70%; Suitable for PCI and side-branch lesions are not expected to stent implantation, and no drug-eluting balloon used for the main-branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches; Residual stenosis of the side-branch lesion ≦50% after pre-treatment, with a TIMI flow grade 3; The target vessel diameter was 2.0mm-4.0mm.  Exclusion Criteria:  Women who is pregnant or lactating, or having a fertility plan within 1 year or are unwilling to take effective contraceptive measures; Cardiogenic shock patients; With hemorrhagic symptoms or active gastrointestinal ulcers, or previous stroke within 6 months, or who are expected to be unable to tolerate double-antibody therapy after interventional therapy; ST-segment elevation myocardial infarction (STEMI) occurred within one week before enrollment; With severe congestive heart failure or NYHA class Ⅳ heart failure; With severe valvuar heart disease; Heart transplant patients; With renal insufficiency (creatinine > 3.0mg/ dL or 265.2 umol /L) and/or advanced renal disease requiring dialysis; With a life expectancy less than 1 year; With contraindications who cannot take aspirin and/or clopidogrel and/or ticagrelor; With known allergies to paclitaxel, sirolimus, contrast agents, etc.; Participating in clinical trials of other drugs or devices and has not met the primary endpoint; Non-target lesions cannot be processed before the target lesions or non-target lesions treatment fails; Intra-stent restenosis; High-risk left main disease; Other patients considered by the investigator to be unsuitable for inclusion.